SG11201911618UA - Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy - Google Patents

Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Info

Publication number
SG11201911618UA
SG11201911618UA SG11201911618UA SG11201911618UA SG11201911618UA SG 11201911618U A SG11201911618U A SG 11201911618UA SG 11201911618U A SG11201911618U A SG 11201911618UA SG 11201911618U A SG11201911618U A SG 11201911618UA SG 11201911618U A SG11201911618U A SG 11201911618UA
Authority
SG
Singapore
Prior art keywords
immunotherapy
predicting
usefulness
methods
amino acid
Prior art date
Application number
SG11201911618UA
Inventor
Ugur Sahin
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of SG11201911618UA publication Critical patent/SG11201911618UA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201911618UA 2017-06-09 2018-06-01 Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy SG11201911618UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2017/064140 WO2018224166A1 (en) 2017-06-09 2017-06-09 Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
PCT/EP2018/064468 WO2018224405A1 (en) 2017-06-09 2018-06-01 Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Publications (1)

Publication Number Publication Date
SG11201911618UA true SG11201911618UA (en) 2020-01-30

Family

ID=59227704

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201911618UA SG11201911618UA (en) 2017-06-09 2018-06-01 Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
SG10201912475XA SG10201912475XA (en) 2017-06-09 2018-06-01 Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912475XA SG10201912475XA (en) 2017-06-09 2018-06-01 Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Country Status (14)

Country Link
US (1) US20200209251A1 (en)
EP (1) EP3635408A1 (en)
JP (2) JP7396903B2 (en)
KR (1) KR102560750B1 (en)
CN (1) CN110741260B (en)
AR (1) AR112601A1 (en)
AU (1) AU2018279117A1 (en)
BR (1) BR112019022349A2 (en)
CA (1) CA3066308A1 (en)
IL (1) IL271031A (en)
MA (1) MA49246A (en)
SG (2) SG11201911618UA (en)
TW (1) TW201920959A (en)
WO (2) WO2018224166A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4046651A1 (en) * 2021-02-23 2022-08-24 baseclick GmbH Method for producing an mrna tumor vaccine
CN115620810B (en) * 2022-12-19 2023-03-28 北京诺禾致源科技股份有限公司 Method and device for detecting exogenous insertion information based on third-generation gene sequencing data

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE512160T1 (en) * 2005-04-26 2011-06-15 Immatics Biotechnologies Gmbh T-CELL EPITOPES FROM THE IMMATURE LAMININ RECEPTOR PROTEIN (ONCOFOETAL ANTIGEN) AND THEIR MEDICAL USES
AU2012261237B2 (en) * 2011-05-24 2017-06-01 BioNTech SE Individualized vaccines for cancer
EP2925348B1 (en) * 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
CA2919567A1 (en) * 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma

Also Published As

Publication number Publication date
CN110741260B (en) 2024-03-08
EP3635408A1 (en) 2020-04-15
BR112019022349A2 (en) 2020-05-26
US20200209251A1 (en) 2020-07-02
MA49246A (en) 2020-04-15
RU2019139982A (en) 2021-07-09
AR112601A1 (en) 2019-11-20
JP2020523016A (en) 2020-08-06
TW201920959A (en) 2019-06-01
KR20200014311A (en) 2020-02-10
WO2018224405A1 (en) 2018-12-13
WO2018224166A1 (en) 2018-12-13
RU2019139982A3 (en) 2021-07-09
CN110741260A (en) 2020-01-31
JP2024026224A (en) 2024-02-28
SG10201912475XA (en) 2020-02-27
AU2018279117A1 (en) 2020-01-02
JP7396903B2 (en) 2023-12-12
CA3066308A1 (en) 2018-12-13
IL271031A (en) 2020-01-30
KR102560750B1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
HK1255383A1 (en) Peptides and antibodies for the removal of biofilms
IL251571A0 (en) Lepidopteran-active cry1da1 amino acid sequence variant proteins
IL259793A (en) Slc45a2 peptides for immunotherapy
IL268731A (en) New uses of anti-sirpg antibodies
IL262680B1 (en) Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
IL264375B (en) Methods of purifying fc-containing proteins
EP3191629A4 (en) Peptide microarrays and novel biomarkers for celiac disease
GB2552749B (en) Shaped charge system having multi-composition liner
EP3383497A4 (en) Novel antibodies for the treatment of cancers
EP3743058A4 (en) Methods for predicting tumor response to immunotherapy
IL253518A0 (en) Assays for highlypositively charged protein
IL248283B (en) Method for the synthesis of clofarabine
SG10202007893TA (en) Methods of immunotherapy
IL271031A (en) Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
EP3509632A4 (en) Immunotherapy for polyomaviruses
IL284816A (en) Methods for improved immunotherapy
IL281720A (en) Hmgb1 protein derivatives for the removal of biofilms
HUE057882T2 (en) Process for the preparation of carbodiimides
EP3285875A4 (en) Methods for the synthesis of ceragenins
GB201821205D0 (en) Immunotherapy
IL254205B (en) Amino acid acylation reagents and methods of using the same
EP3288560A4 (en) Methods for the synthesis of ceragenins